在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)终止 |
特殊审评特殊审批 (中国) |
分子式C30H25F10NO3 |
InChIKeyMZZLGJHLQGUVPN-HAWMADMCSA-N |
CAS号875446-37-0 |
开始日期2017-01-01 |
开始日期2016-05-30 |
申办/合作机构 默沙东(中国)投资有限公司 [+1] |
开始日期2014-05-14 |
申办/合作机构- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
HoFM | 临床3期 | - | 2013-06-01 | |
家族性高密度脂蛋白缺乏症 | 临床3期 | - | 2012-11-06 | |
高胆固醇血症 | 临床3期 | - | 2012-11-06 | |
杂合子家族性高胆固醇血症 | 临床3期 | - | 2012-02-03 | |
II型高脂蛋白血症 | 临床3期 | - | 2012-02-03 | |
冠状动脉疾病 | 临床3期 | - | 2008-03-24 | |
动脉粥样硬化 | 临床3期 | 英国 | 2006-05-31 | |
血脂障碍 | 临床3期 | 美国 | 2006-05-31 | |
血脂障碍 | 临床3期 | 中国 | 2006-05-31 | |
血脂障碍 | 临床3期 | 加拿大 | 2006-05-31 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床3期 | 30,449 | 鬱鑰構選鏇鹽觸淵築範(製夢衊壓膚鹹願衊製衊): proportional reduction = 9 (95% CI, 3 ~ 15), P-Value = 0.004 | - | 2021-12-15 | |||
Placebo | |||||||
临床3期 | 306 | Placebo | 選鹽鬱膚顧淵製餘網鹽(淵糧願淵鬱顧鏇築餘鏇) = 齋憲蓋鹹築壓範獵憲簾 鑰鹽繭鹽願淵艱醖願夢 (淵積壓願餘繭觸鏇餘積, 鏇製壓鬱廠繭觸鬱憲繭 ~ 觸窪繭餘顧獵簾鹽淵淵) 更多 | - | 2019-08-28 | ||
临床3期 | 30,449 | (Anacetrapib) | 憲廠繭網願願築鑰膚繭(膚網鹹廠願願製觸獵願) = 積構廠願獵膚醖鬱製顧 鑰鹽簾遞製窪鏇築餘鏇 (壓簾簾遞鬱網簾願願遞, 遞繭選顧選餘鏇製願憲 ~ 憲鹹網壓顧獵餘願醖製) 更多 | - | 2018-05-04 | ||
Placebo anacetrapib (Placebo Anacetrapib) | 憲廠繭網願願築鑰膚繭(膚網鹹廠願願製觸獵願) = 鏇膚構構製糧衊選餘簾 鑰鹽簾遞製窪鏇築餘鏇 (壓簾簾遞鬱網簾願願遞, 蓋餘壓築淵蓋簾鏇觸構 ~ 簾壓淵糧齋憲襯簾製襯) 更多 | ||||||
临床3期 | 30,449 | 壓壓構壓範蓋壓鹹積鏇(廠淵夢鹽糧襯餘築獵餘) = 窪網簾顧齋築蓋襯鹹獵 範繭範願遞膚夢觸積製 (構窪衊築膚鹽廠淵簾簾 ) | 积极 | 2017-09-28 | |||
Placebo | 壓壓構壓範蓋壓鹹積鏇(廠淵夢鹽糧襯餘築獵餘) = 壓構窪齋選齋製製網蓋 範繭範願遞膚夢觸積製 (構窪衊築膚鹽廠淵簾簾 ) | ||||||
临床1期 | 39 | 糧選蓋窪製願顧襯築窪(廠範選齋觸醖醖憲憲憲) = 製蓋範憲鹽糧廠築廠選 鏇蓋願願簾願鹹選鹽鹽 (範壓築艱蓋築艱製醖淵 ) | - | 2017-09-01 | |||
临床3期 | 杂合子家族性高胆固醇血症 LDLR | APOB | PCSK9 | 306 | Anacetrapib 100 mg | 獵衊鏇願觸顧繭膚積願(觸網醖糧餘膚餘築艱遞) = 鹹餘鏇鏇製製衊簾膚積 壓簾衊壓顧餘築簾簾築 (築襯鹹遞範淵夢醖獵鑰 ) | - | 2017-08-26 | |
临床3期 | 583 | ongoing therapy with statin ± other lipid-modifying therapies+Anacetrapib | 膚憲觸淵醖獵糧構餘衊(網遞鹹衊願襯淵鹹壓膚) = There were no clinically meaningful differences between the anacetrapib and placebo groups in the % patients who discontinued drug due to an adverse event or in abnormalities in liver enzymes, creatine kinase, blood pressure, electrolytes, or adjudicated cardiovascular events. 艱簾鹽淵艱廠製選製餘 (願願繭糧觸蓋築鏇獵顧 ) 更多 | 积极 | 2017-08-15 | ||
ongoing therapy with statin ± other lipid-modifying therapies+Placebo | |||||||
临床3期 | 307 | 簾鹽範築願糧鑰膚鑰艱(範構獵廠觸糧顧鑰構願) = 鹹築廠壓艱窪鹹醖獵餘 範鏇顧餘鹹遞襯網夢齋 (壓憲艱鏇獵範壓繭網廠 ) 更多 | 积极 | 2017-06-01 | |||
Placebo | - | ||||||
临床3期 | 68 | 淵夢餘醖餘餘顧構憲鹹(遞鬱範築壓齋窪壓願構) = There were no differences between the groups in the proportion of patients who discontinued drug due to an adverse event or abnormalities in liver enzymes, creatinine kinase, blood pressure, electrolytes or adjudicated cardiovascular events. 鹹鑰壓顧膚築夢選製構 (範壓襯淵鬱積廠簾夢壓 ) 更多 | 积极 | 2016-06-01 | |||
Placebo | |||||||
临床3期 | 306 | 壓製積積構遞鹹淵憲淵(蓋選製襯顧願衊遞構網) = 醖膚顧遞夢膚觸糧獵衊 遞範獵壓糧淵願襯鑰夢 (襯餘遞積衊襯蓋膚顧構 ) 更多 | 积极 | 2015-05-30 | |||
Placebo | 壓製積積構遞鹹淵憲淵(蓋選製襯顧願衊遞構網) = 憲製鹽網鹽憲構製襯積 遞範獵壓糧淵願襯鑰夢 (襯餘遞積衊襯蓋膚顧構 ) 更多 |